Greenhaven Road Capital is a boutique hedge fund founded by Scott Miller, focused on overlooked small-cap value stocks with a concentrated, low-turnover book, plus a Partners Fund that seeds emerging managers. Its candid quarterly letters are known for surfacing obscure ideas; AUM is roughly $600m.
This investor letter dives into a stock called HKHC, a small asset manager that’s being overlooked. Its stock fell by a third in 2025, yet cash and investments alone are worth $20.63 per share—almost the same as the $23.50 stock price. Plus, its core business and future performance fees add even more value. The fund manager thinks the market is missing this. For everyday investors, it’s a reminder to look beyond big, famous companies. Some hidden gems might be cheap because they’re tiny or trade on obscure exchanges. But always check the numbers and risks yourself. No hype.
Greenhaven Road’s report discusses the fourth quarter and full-year 2025 results, with the Partners Fund delivering net returns of approximately 2% (quarterly) and 14% (full year). The core argument is that the fund’s criteria for selecting managers—such as a one-person investment committee, concent
This chapter discusses the performance of the Greenhaven Road Partners Fund in the fourth quarter and full year of 2025, with a focus on analyzing the investment logic behind a "hidden company"—Horizon Kinetics Holding Company (HKHC). The market backdrop is that large-cap tech companies (Magnificent 7) continued to achieve 20%+ revenue growth in 2025 and commanded higher valuations, while the fund faced headwinds due to its stock selection criteria favoring small, low-attention companies.
The author's core investment argument is that HKHC is a "hidden company" significantly undervalued by the market. Its stock price fell by one-third in 2025 (ending the year at approximately $23.50), yet its fundamentals are strong, with intrinsic value far exceeding the current share price. The counterintuitive judgment lies in the fact that although HKHC has no analyst coverage, trades over-the-counter, and is not included in major indices, its management is the largest shareholder. The company's value, derived from cash and balance sheet investments, its core asset management business, and future incentive fees, presents a significant discount at the current stock price.
| Value Component | Data/Estimate | Notes |
|---|---|---|
| Cash and Balance Sheet Investments | $20.63 per share (as of September 30, 2025) | Covers over 85% of year-end stock price |
| 2024 Incentive Fees | Over $2 per share | Near zero in 2025 |
| Expected 2026 Incentive Fees | Approximately $1 per share (MIAX IPO) | Estimated at 5x P/E |
| Core Asset Management Operating Income | ~$1.15 per share in 2025, ~$1.30 per share in 2026 | 16x P/E estimate exceeds $20 per share |
For investors, HKHC's current stock price ($23.50) is far below the sum of its cash and investments ($20.63) and core business value (over $20 per share), offering a significant margin of safety. The recommendation is to focus on such "hidden companies"—those overlooked due to structural reasons (size, liquidity, listing venue, index rules) but with strong fundamentals and high management alignment. Specific direction: indirectly allocate to inflation-benefiting assets (energy, precious metals royalties, real estate, etc.) through HKHC, and capitalize on the volatility of its incentive fees by entering at low points.
The continuation further reinforces Greenhaven Road's rigorous approach to disclosure, particularly across four dimensions: information completeness and reliability, index usage, net performance calculation, and legal compliance. These details not only reflect standard practices in the hedge fund industry but also reveal strategies to protect the firm from legal risk while conveying transparency to investors.
| Index | 2023 Total Return (Including Dividends) | Industry Concentration (Top 3 Sectors as % of Total) | Median Market Cap |
|---|---|---|---|
| S&P 500 | 26.2% | Technology (28%), Healthcare (13%), Financials (12%) | ~$30 billion |
| Russell 2000 | 16.9% | Financials (18%), Healthcare (16%), Industrials (14%) | ~$3 billion |
Compared to peers, Greenhaven Road's disclosure is at a moderate level:
| Dimension | Greenhaven Road | Typical Hedge Fund (e.g., Citadel) | Private Equity Fund (e.g., Blackstone) |
|---|---|---|---|
| Performance Disclosure | Net performance with fee assumptions | Typically provides only gross returns | Provides IRR and MOIC |
| Index Usage | Explicitly not a benchmark | Often uses custom benchmarks | Rarely mentions indices |
| Legal Risk Statement | Comprehensive disclaimers | Similar but more concise | Emphasizes "non-public" more |
| Investor Restrictions | Not explicitly stated | Typically requires accredited investors | Requires qualified purchasers |
Through precise legal language and assumption explanations, the continuation constructs an information-asymmetric but risk-controlled investor communication framework. While protecting itself from litigation, Greenhaven Road also signals to investors: "We have disclosed to the best of our ability, but the decision is yours." For potential investors, the key is to understand:
This disclosure style is common among mature hedge funds, but novice investors may underestimate its implied complexity.